Why the study?
Although recent evidence suggests the superiority of 4F-PCC over plasma for on-label indications, the off-label use of 4F-PCC has not been rigorously studied.
Does off-label use of 4F-PCC compared to on-label use affect in-hospital mortality and blood utilization?
Does off-label use of 4F-PCC compared to on-label use affect in-hospital mortality and blood utilization?
Off-label use of 4F-PCC is associated with significantly higher in-hospital mortality and blood utilization compared to on-label use, despite similar high costs.
Off-label 4F-PCC use was associated with higher mortality; hypothesis-generating and should not change practice without prospective trials.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: